

extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to the OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below.

The OMB is particularly interested in comments that will help:

1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to be collected;
4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses; and
5. Assess information collection costs.

Proposed Project

Traveler-Based Genomic Surveillance Program (TGS) Traveler Questionnaire (OMB Control No. 0920–1406, Exp. 6/30/2026)—Revision—National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

The goal of CDC's Traveler-Based Genomic Surveillance program (TGS) is to monitor for communicable diseases among arriving international travelers at select U.S. airports. Doing so enables the early detection of communicable disease importations of public health concern. The program also fills gaps in global biosurveillance by monitoring trends in global circulation of communicable diseases. Travelers who volunteer to participate in the program at airports and provide written, informed consent complete a short, anonymous questionnaire asking for travel information and general demographics. Two lower nasal swabs are then self-collected from participants. One swab is pooled with other traveler swabs in batches of 5–10 samples. Pooled samples undergo initial testing for pathogens of public health importance (including SARS-CoV–2, Influenza A

virus, and RSV [respiratory syncytial virus]) via reverse transcription polymerase chain reaction (RT–PCR) testing. If any pool of swabs registers with any positive test, then all secondary swab samples (stored individually) corresponding to those in the pool are tested individually. Pathogen genomic sequencing may be performed on samples to determine the pathogen lineage. Some samples may be sent to CDC for further testing. No human genetic testing will be performed.

This request is a Revision of the approved collection request titled: Traveler-Based Genomic Surveillance (OMB Control No. 0920–1406). The program has since broadened to include testing nasal swabs for pathogens beyond SARS-CoV–2. The program has also streamlined the questions asked of participants based on data from previous versions of the questionnaire, participant feedback received through program staff at the airports, and direct input from the program staff at the airports. The new information collection has fewer questions, and question wording has been updated to improve participant comprehension and response rates.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total burden (in hours)
General Public (International traveler).	Traveler-Based Genomic Surveillance Traveler Questionnaire.	500,000	1	4/60	33,333
Total	33,333

Jeffrey M. Zirger,

Lead, Information Collection Review Office, Office of Public Health Ethics and Regulations, Office of Science, Centers for Disease Control and Prevention.

[FR Doc. 2026–00420 Filed 1–12–26; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day–26–0004; Docket No. CDC–2026–0003]

Proposed Data Collection Submitted for Public Comment and Recommendations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice with comment period.

SUMMARY: The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal

agencies the opportunity to comment on continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled National Disease Surveillance Program—II. Disease Summaries information collection. This collection is used to determine the prevalence of diseases and for the planning and evaluation of programs that prevent and control infectious disease.

DATES: CDC must receive written comments on or before March 16, 2026.

ADDRESSES: You may submit comments, identified by Docket No. CDC–2026–0003 by either of the following methods:

- *Federal eRulemaking Portal:* www.regulations.gov. Follow the instructions for submitting comments.